e-Therapeutics announces the appointment of Christine Soden as non-executive director, and the retirement of Brad Hoy who has served on the e-Therapeutics Board as a non-executive director for nine years.
Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine Soden as non-executive director, and the retirement of Brad Hoy who has served on the e-Therapeutics Board as a non-executive director for nine years. Christine will take over from Brad Hoy as Chair of the Board’s Audit & Risk Committee.
Christine Soden BSc, ACA qualified with Price Waterhouse and has extensive financial management experience in the healthcare industry, having been Group Financial Controller at Medeva plc before serving as CFO in several public healthcare companies including Optos plc, BTG plc, and Celltech Chiroscience plc. Currently Christine is CFO at Acacia Pharma Group Limited and is a non-executive director at two private biotech companies.
Iain Ross, Chairman of e-Therapeutics commented: “We are delighted to be able to welcome Christine to the Board of e-Therapeutics plc. She brings a wealth of relevant experience as we look to build the Company going forward. I would also like to thank Brad Hoy on behalf of the Company for his service and commitment over the last nine years and also to personally thank him for his support during my tenure as Chairman.”
The following additional information is provided in accordance with Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies.
Christine Helen Soden, aged 60, has no shareholding in e-Therapeutics plc. Her current and previous directorships or partnerships are detailed below:
Current directorships and partnerships:
Acacia Pharma Group Limited
Acacia Pharma Limited
Fertility Focus Limited
Futurenova Limited
Past directorships and partnerships held within the last 5 years:
CT2 Holdings Limited
CT2 Limited
Electrical Geodesics, Inc.
There is no further information to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.
